Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Glucagon-like peptide 2 reduces gastric acid secretion

Research in this month's Gastroenterology finds that glucagon-like peptide 2 stimulates glucagon secretion, lipid absorption, and inhibits gastric acid secretion, but does not influence gastric emptying.

News image

fiogf49gjkf04

The gut-derived peptide glucagon-like peptide 2 has been suggested as a potential drug candidate for the treatment of various intestinal diseases.

However, the acute effects of glucagon-like peptide 2 on gastric functions as well as on glucose and lipid homeostasis in humans are less well characterized.

Dr Juris Meier and colleagues assessed pentagastrin-stimulated gastric acid output.

The team studied 15 healthy male volunteers with the intravenous infusion of glucagon-like peptide 2 or placebo over 120 minutes in the fasting state.

Another 15 healthy male volunteers were studied with 390 minutes infusion of glucagon-like peptide 2 or placebo during the ingestion of a solid test meal.

The research team determined gastric emptying using a 13C-sodium-octanote breath test.

There was a 15% reduction in gastric acid and chloride secretion
Gastroenterology

Plasma concentrations of glucose, insulin, C-peptide, glucagon, glucagon-like peptide 2, free fatty acids, free glycerol, and triglycerides were determined.

The researchers found that glucagon-like peptide 2 administration led to a marked increase in glucagon concentrations.

This increase in glucagons was noted both in the fasting state and during the meal study.

Postprandial plasma concentrations of triglycerides and free fatty acids were higher during glucagon-like peptide 2 infusion compared with placebo.

The team observed that glycerol concentrations were similar.

Glucagon-like peptide 2 administration caused a 15% reduction in pentagastrin-stimulated gastric acid and chloride secretion.

However, the team found that gastric emptying was not affected.

Dr Meier's team concluded, “Glucagon-like peptide 2 reduces gastric acid secretion but does not seem to have an influence on gastric emptying.”

“The stimulation of glucagon secretion by glucagon-like peptide 2 may counteract the glucagonostatic effect of glucagon-like peptide -1.”

“Changes in postprandial lipid excursions seem to reflect enhanced intestinal nutrient absorption during glucagon-like peptide 2 administration.”

Gastroenterol 2006: 130(1): 44-54
19 January 2006

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us